Last reviewed 2026-05-20 · How we verify

Piazolin (MORINAMIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Piazolin (generic name: MORINAMIDE) is a morinamide drug. It is currently in Phase 2 development.

Morinamide works by interacting with cellular processes to produce its effects.

Piazolin is a small molecule with the synonyms MORINAMIDA, MORINAMIDE, and MORINAMIDE HCL, among others.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MORINAMIDE
Drug class	morinamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells are like a orchestra, and morinamide is like a conductor that helps the different parts work together in a specific way. This can help to restore balance and normal function to the cells, which can be beneficial for treating certain conditions. However, the exact details of how morinamide conducts the orchestra are still not fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Piazolin CI brief — competitive landscape report
Piazolin updates RSS · CI watch RSS

Frequently asked questions about Piazolin

What is Piazolin?

Piazolin (MORINAMIDE) is a morinamide drug.

How does Piazolin work?

Morinamide works by interacting with cellular processes to produce its effects.

What is the generic name of Piazolin?

MORINAMIDE is the generic (nonproprietary) name of Piazolin.

What drug class is Piazolin in?

Piazolin belongs to the morinamide class. See all morinamide drugs at /class/morinamide.

What development phase is Piazolin in?

Piazolin is in Phase 2.

Drug class: All morinamide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing